Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

A volumetric study of basal ganglia structures in individuals with early-treated phenylketonuria.

Bodner KE, Aldridge K, Moffitt AJ, Peck D, White DA, Christ SE.

Mol Genet Metab. 2012 Nov;107(3):302-7. doi: 10.1016/j.ymgme.2012.08.007. Epub 2012 Aug 18.

PMID:
23006929
2.

Developmentally stable whole-brain volume reductions and developmentally sensitive caudate and putamen volume alterations in those with attention-deficit/hyperactivity disorder and their unaffected siblings.

Greven CU, Bralten J, Mennes M, O'Dwyer L, van Hulzen KJ, Rommelse N, Schweren LJ, Hoekstra PJ, Hartman CA, Heslenfeld D, Oosterlaan J, Faraone SV, Franke B, Zwiers MP, Arias-Vasquez A, Buitelaar JK.

JAMA Psychiatry. 2015 May;72(5):490-9. doi: 10.1001/jamapsychiatry.2014.3162.

PMID:
25785435
3.

Tract-based evaluation of white matter damage in individuals with early-treated phenylketonuria.

Peng H, Peck D, White DA, Christ SE.

J Inherit Metab Dis. 2014 Mar;37(2):237-43. doi: 10.1007/s10545-013-9650-y. Epub 2013 Sep 17.

PMID:
24043380
4.

Neurocognitive functioning in adults with phenylketonuria: results of a long term study.

Weglage J, Fromm J, van Teeffelen-Heithoff A, Möller HE, Koletzko B, Marquardt T, Rutsch F, Feldmann R.

Mol Genet Metab. 2013;110 Suppl:S44-8. doi: 10.1016/j.ymgme.2013.08.013. Epub 2013 Aug 31.

PMID:
24071437
5.

Disruption of prefrontal function and connectivity in individuals with phenylketonuria.

Christ SE, Moffitt AJ, Peck D.

Mol Genet Metab. 2010;99 Suppl 1:S33-40. doi: 10.1016/j.ymgme.2009.09.014.

PMID:
20123468
6.

Morphometric analysis of gray matter integrity in individuals with early-treated phenylketonuria.

Christ SE, Price MH, Bodner KE, Saville C, Moffitt AJ, Peck D.

Mol Genet Metab. 2016 May;118(1):3-8. doi: 10.1016/j.ymgme.2016.02.004. Epub 2016 Feb 16.

PMID:
26947918
7.

Altered white matter/gray matter proportions in the striatum of patients with schizophrenia: a volumetric MRI study.

Tamagaki C, Sedvall GC, Jönsson EG, Okugawa G, Hall H, Pauli S, Agartz I.

Am J Psychiatry. 2005 Dec;162(12):2315-21.

PMID:
16330596
8.

Beyond executive function: non-executive cognitive abilities in individuals with PKU.

Janzen D, Nguyen M.

Mol Genet Metab. 2010;99 Suppl 1:S47-51. doi: 10.1016/j.ymgme.2009.10.009. Review.

PMID:
20123470
9.

Decreased functional brain connectivity in individuals with early-treated phenylketonuria: evidence from resting state fMRI.

Christ SE, Moffitt AJ, Peck D, White DA, Hilgard J.

J Inherit Metab Dis. 2012 Sep;35(5):807-16. doi: 10.1007/s10545-011-9439-9. Epub 2012 Jan 10.

PMID:
22231384
10.

Unrestricted free-choice ethanol self-administration in rats causes long-term neuroadaptations in the nucleus accumbens and caudate putamen.

Nestby P, Vanderschuren LJ, De Vries TJ, Mulder AH, Wardeh G, Hogenboom F, Schoffelmeer AN.

Psychopharmacology (Berl). 1999 Jan;141(3):307-14.

PMID:
10027512
11.

An MRI study of the basal ganglia in autism.

Sears LL, Vest C, Mohamed S, Bailey J, Ranson BJ, Piven J.

Prog Neuropsychopharmacol Biol Psychiatry. 1999 May;23(4):613-24.

PMID:
10390720
12.

Neuropsychological functioning in children with early-treated phenylketonuria: impact of white matter abnormalities.

Anderson PJ, Wood SJ, Francis DE, Coleman L, Warwick L, Casanelia S, Anderson VA, Boneh A.

Dev Med Child Neurol. 2004 Apr;46(4):230-8.

13.

Extensive deep gray matter volume reductions in children and adolescents with fetal alcohol spectrum disorders.

Nardelli A, Lebel C, Rasmussen C, Andrew G, Beaulieu C.

Alcohol Clin Exp Res. 2011 Aug;35(8):1404-17. doi: 10.1111/j.1530-0277.2011.01476.x. Epub 2011 May 16.

PMID:
21575012
14.

Cognitive profile and mental health in adult phenylketonuria: A PKU-COBESO study.

Jahja R, Huijbregts SCJ, de Sonneville LMJ, van der Meere JJ, Legemaat AM, Bosch AM, Hollak CEM, Rubio-Gozalbo ME, Brouwers MCGJ, Hofstede FC, de Vries MC, Janssen MCH, van der Ploeg AT, Langendonk JG, van Spronsen FJ.

Neuropsychology. 2017 May;31(4):437-447. doi: 10.1037/neu0000358. Epub 2017 Mar 20.

PMID:
28318283
16.

White matter integrity and executive abilities in individuals with phenylketonuria.

Antenor-Dorsey JA, Hershey T, Rutlin J, Shimony JS, McKinstry RC, Grange DK, Christ SE, White DA.

Mol Genet Metab. 2013 Jun;109(2):125-31. doi: 10.1016/j.ymgme.2013.03.020. Epub 2013 Apr 6.

17.

Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU).

Burton BK, Bausell H, Katz R, Laduca H, Sullivan C.

Mol Genet Metab. 2010 Oct-Nov;101(2-3):110-4. doi: 10.1016/j.ymgme.2010.06.015. Epub 2010 Jun 27.

PMID:
20638313
18.

White matter integrity and executive abilities following treatment with tetrahydrobiopterin (BH4) in individuals with phenylketonuria.

White DA, Antenor-Dorsey JA, Grange DK, Hershey T, Rutlin J, Shimony JS, McKinstry RC, Christ SE.

Mol Genet Metab. 2013 Nov;110(3):213-7. doi: 10.1016/j.ymgme.2013.07.010. Epub 2013 Jul 19.

19.

Psychiatric disorders in adult patients with early-treated phenylketonuria.

Pietz J, Fätkenheuer B, Burgard P, Armbruster M, Esser G, Schmidt H.

Pediatrics. 1997 Mar;99(3):345-50.

PMID:
9041285
20.

Mental health and social functioning in early treated Phenylketonuria: the PKU-COBESO study.

Jahja R, Huijbregts SC, de Sonneville LM, van der Meere JJ, Bosch AM, Hollak CE, Rubio-Gozalbo ME, Brouwers MC, Hofstede FC, de Vries MC, Janssen MC, van der Ploeg AT, Langendonk JG, van Spronsen FJ.

Mol Genet Metab. 2013;110 Suppl:S57-61. doi: 10.1016/j.ymgme.2013.10.011. Epub 2013 Oct 22.

PMID:
24183792

Supplemental Content

Support Center